Abstract
IntroductionImmunotherapy is a well-established treatment option in patients with metastatic melanoma. However, biomarkers that can be used to predict a response in these patients have not yet been found, putting patients at risk of severe side effects.MethodsIn this retrospective analysis, we investigated the association between the body mass index and ipilimumab treatment response in patients with metastatic melanoma. Patients with metastatic melanoma who received a monotherapy of up to 4 doses of ipilimumab (3 mg/kg) every 3 weeks from 2011 to 2014 in three major hospitals in Austria were included. Patients were classified into two groups: normal group (BMI<25) and overweight group (BMI≥25).Results40 patients had a normal BMI, and 36 had a BMI above normal. Patients with a BMI that was above normal showed significantly higher response rates (p = 0.024, χ2), and lower likelihood of brain metastases (p = 0.012, χ2). No differences were found between both groups with respect to gender (p = 0.324, χ2), T-stage (p = 0.197, χ2), or the occurrence of side effects (p = 0.646, χ2). Patients with a BMI above normal showed a trend towards longer overall survival (p = 0.056, Log-Rank), but no difference was found regarding progression-free survival (p = 0.924, Log-Rank).ConclusionsThe BMI correlated with the response to ipilimumab treatment in a cohort of metastatic melanoma patients.
Highlights
MethodsWe investigated the association between the body mass index and ipilimumab treatment response in patients with metastatic melanoma
Immunotherapy is a well-established treatment option in patients with metastatic melanoma
The Body Mass Index (BMI) correlated with the response to ipilimumab treatment in a cohort of metastatic melanoma patients
Summary
We investigated the association between the body mass index and ipilimumab treatment response in patients with metastatic melanoma. Patients with metastatic melanoma who received a monotherapy of up to 4 doses of ipilimumab (3 mg/kg) every 3 weeks from 2011 to 2014 in three major hospitals in Austria were included. We performed a retrospective study in patients who received treatment with ipilimumab monotherapy for metastatic melanoma from 2011 to 2014 in three hospitals in Austria. Body mass index may predict response to ipilimumab in metastatic melanoma approved dose of 3 mg/kg per dose every 3 weeks. PFS was calculated from the date of treatment initiation to the date of progression as documented by imaging (CT-scan), clinical examination, or death. The patients were dichotomized into two groups, i.e., in a patient group with a BMI lower than 25 kg/m2 (normal weight group) and patient group with a BMI higher than or exactly 25 kg/m2 (overweight group)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
